目的:观察多西他赛联合卡培他滨(希罗达)治疗转移乳性腺癌的疗效及不良反应.方法:56例乳腺癌患者采用多西他赛联合卡培他滨治疗,第1天静脉滴注多西他赛75 mg/m2;第1～14天口服卡培他滨900 mg/m2,每天2次,21 d为1周期,4周期后评价疗效.结果:56例患者治疗后均取得较好疗效,不良反应主要为胃肠道反应、骨髓抑制和肝功能损害,均可经过对症支持治疗可逆性恢复,无治疗相关死亡患者.结论:多西他赛联合卡培他滨治疗转移性乳腺癌疗效较好,不良反应可耐受.%Objective: To study the efficacy and toxicity of Docetaxel and Xeloda combination regimen in treatment of patients with metastatic breast cancer.Methods: Fifty-six patients received Docetaxel and Xeloda combination regimen, namely, Docetaxel 75 mg/m2 ivgtt, dayl; Xeloda 900 mg/m2, twice daily.The regimen was repeated every 21 days and the clinical response was recorded after four cycles.Results: Fifty-six patients were evaluated that who obtain better curative effect.The main toxicities were gastrointestinal, myelosuppression toxicity and liver function defective, and were tolerable.There was no death associated with treatment.Conclusion: Docetaxel and Xeloda combination regimen is effective for metastatic breast cancer and well-tolerated.
展开▼
